Antimicrobial resistance: we need to act now
Antimicrobial drugs are undervalued for their revolutionary impact on human society. Their discovery in the early 20th century corresponds with a dramatic increase in global life expectancy. Thanks to the development of various classes of antimicrobial agents throughout the last century, death at the hands of bacterial infection has become significantly less of a risk. However, the emergence of drug-resistant bacteria serves to dilute the effectiveness of antimicrobial agents. Andrea Chiarello (Pfizer), Chair, Healthcare Committee shares why we need to act now on antimicrobial resistance.
Related items
:focal())
Healthcare, competitiveness, innovation and simplification
Europe’s life sciences sector sits at the heart of the EU’s competitiveness agenda. It supports advanced manufacturing and helps bring new treatments and technologies to patients. Yet companies deciding where to invest need a regulatory environment that is predictable and open to global cooperation.
The European Commission’s work on the Biotech Act and the targeted revision of the Medical Devices and In Vitro Diagnostics Regulations (MDR/IVDR) offers an opportunity to improve that environment. Both files can help make Europe a stronger location for life sciences investment.
The EU should use this moment to build a framework that keeps pace with scientific progress. That means faster and clearer procedures. It also means better use of data and intellectual property rules that recognise the realities of global supply chains.
:focal())
Strengthening EU competitiveness through an adaptive MDR/IVDR framework
A global approach to strengthening Europe’s biotechnology ecosystem
Policy priorities
Insights and advocacy driving Europe’s policy agenda. Our priorities support growth, innovation and a stronger transatlantic economy.
Membership
Connecting business and policymakers to strengthen the voice of American companies in Europe.